Interní Med. 2001; 3(2): 62-66

Prevence cévních mozkových příhod z hlediska internisty

MUDr. Pavel Sedloň, MUDr. Ilja Kotík
I. interní odd. s JIP, Ústřední vojenská nemocnice Praha

Keywords: cévní onemocnění mozku, prevence, léčba, rizikové faktory.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sedloň P, Kotík I. Prevence cévních mozkových příhod z hlediska internisty. Interní Med. 2001;3(2):62-66.

Cévní onemocnění mozku (COM) tvoří významnou příčinu morbidity i mortality obyvatel České republiky. Léčba proběhlých příhod je nákladná a málo efektivní, proto považujeme za rozhodující prevenci těchto onemocnění. V článku jsme se pokusili shrnout nejnovější poznatky o nejčastějších příčinách cévních mozkových příhod a podat přehled účinných a velkými klinickými studiemi ověřených preventivních postupů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zdraví pro všechny do roku 2000, Monitoring 1993-1994. Česká republika. ÚZIS ČR 1994, s. 259.
    2. Skřivánek O, Hošek M, et col.: Hospitalizační úmrtnost na cévní mozkovou příhodu. Kardio 88, 8, 1988, 6-18.
    3. Giroud M., Creisson E et col.: Risk factors for primary cerebral hemorhage: a population based study-The Stroke registry in Dijon. Neuroepidemiology, 1995, 14:1, 20-6. Go to original source... Go to PubMed...
    4. Lukovits TG, Mazzone TM.: Diabetes mellitus and cerebrovascular disease. Neuroepidemiology 1999, 18(1): 1-14. Go to original source... Go to PubMed...
    5. Wolf AP.: Prevention of stroke. Lancet 1998, 352 (suppl III) 15-18. Go to original source... Go to PubMed...
    6. Hansson L., Limdholm LH, et col.: Effekt of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999 Feb, 353(9153): 611-6. Go to original source... Go to PubMed...
    7. Hansson L.: The Hypertension Optimal Treatment study nad the importance of lowering blood presure. J Hypertens Suppl, 1999 Feb, 17:1, S9-13.
    8. Antikainen R. et. col.: Therapy in old patients with isolated systolic hypertension, fouth progress report on the Syst-Eur trial. J Hum Hypertens, 1997 May, 11:5, 263-9. Go to original source... Go to PubMed...
    9. SHEP cooperative research group.: Prevention of stroke by antihypertenzive drug treatment in older persons with isolated systolic hypertension. Final results of The Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 Jun, 265:24, 3255-64.
    10. Collins R, Peto R. et.col.: Blood presure, stroke and coronary heart disease. Part II, efekt of short term reductions in blood presure - An overwiew of the uncounfounded randomised drug trials in an epidemiological context. Lancet 1990, 335: 827-839. Go to original source... Go to PubMed...
    11. Ezekowitz, Levine.: Preventing stroke in patients with atrial fibrillation. JAMA 1999 May, 281(19): 1830-5. Go to original source... Go to PubMed...
    12. The SPAF III investigators.: Adjusted-dose warfarin vers. low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996 Sep, 348: 9028, 633-8.
    13. The SPAF III writing committee for The Stroke Prevention in Atrial Fibrillation Investigators.: Patient with nonvalvular atrial fibrillation at low risk of stroke during treatment of aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA 1998 Apr, 279(16): 1273-7. Go to PubMed...
    14. Prospective Studies Collaboration.: Cholesterol, diastolic blood presure, and stroke. Lancet 1995, 346, 1647-58. Go to original source...
    15. 14.Iso H, Jacobs DR, et col.: Serum cholesterol levels and six year mortality from stroke in 350977 men screened for The Multiple Risk Faktor Intervention Trial. NEJM. 1989, 320: 904-910.
    16. 15.Yano K, Reed DM.: Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989, 20: 1460-65. Go to PubMed...
    17. The CARE investigators: Reduction of stroke incidence after myokardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. Circulation 1999 Jan 19, 99(2): 216-23. Go to original source... Go to PubMed...
    18. Scandinavian Simvastatin Survival Study group.: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease, The Simvastatin Scandinavian Survival Study (4S). Lancet 1994, 344: 351-74.
    19. Bousser MG.: Antiplatelet agent and anticoagulant in stroke prevention, neuv.
    20. Crouse jr 3rd, Byington R.: HMG-CoA reductase inhibitor terapy and stroke risk reduction, an analysis of clinical trials data. Atherosclerosis 1998 May, 138 (1):11-24.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.